Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models

Receptor interacting protein kinase-1 and -3 (RIP1 and RIP3) are essential mediators of cell death processes and participate in inflammatory responses. Our group recently demonstrated that gene deletion of Rip3 or pharmacological inhibition of RIP1 attenuated pathogenesis of abdominal aortic aneurysm (AAA), a life-threatening degenerative vascular disease characterized by depletion of smooth muscle cells (SMCs), inflammation, negative extracellular matrix remodeling, and progressive expansion of aorta. The goal of this study was to develop drug candidates for AAA and other disease conditions involving cell death and inflammation. We screened 1141 kinase inhibitors for their ability to block necroptosis using the RIP1 inhibitor Necrostatin-1s (Nec-1s) as a selection baseline. Positive compounds were further screened for cytotoxicity and virtual binding to RIP3. A cluster of top hits, represented by GSK2593074A (GSK’074), displayed structural similarity to the established RIP3 inhibitor GSK’843. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK’074 inhibited necroptosis with an IC50 of ~3 nM. Furthermore, GSK’074, but not Nec-1s, blocked cytokine production by SMCs. Biochemical analyses identified both RIP1 and RIP3 as the biological targets of GSK’074. Unlike GSK’843 which causes profound apoptosis at high doses (>3 µM), GSK’074 showed no detectable cytotoxicity even at 20 µM. Daily intraperitoneal injection of GSK’074 at 0.93 mg/kg significantly attenuated aortic expansion in two mouse models of AAA (calcium phosphate: DMSO 66.06 ± 9.17% vs GSK’074 27.36 ± 8.25%, P < 0.05; Angiotensin II: DMSO 85.39 ± 15.76% vs GSK’074 36.28 ± 5.76%, P < 0.05). Histologically, GSK’074 treatment diminished cell death and macrophage infiltration in aneurysm-prone aortae. Together, our data suggest that GSK’074 represents a new class of necroptosis inhibitors with dual targeting ability to both RIP1 and RIP3. The high potency and minimum cytotoxicity make GSK’074 a desirable drug candidate of pharmacological therapies to attenuate AAA progression and other necroptosis related diseases.

[1]  Michelle C. Schaeffer,et al.  Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. , 2017, Journal of medicinal chemistry.

[2]  J. Bertin,et al.  Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice , 2017, Stroke.

[3]  Xiaodong Wang,et al.  RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality , 2015, Proceedings of the National Academy of Sciences.

[4]  W. Kaiser,et al.  DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. , 2012, Cell host & microbe.

[5]  Kenta Moriwaki,et al.  The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.

[6]  J. Bertin,et al.  K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo , 2016, Cell Death and Differentiation.

[7]  Michelle C. Schaeffer,et al.  Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. , 2013, ACS medicinal chemistry letters.

[8]  Deepak Bandyopadhyay,et al.  DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors. , 2016, Journal of medicinal chemistry.

[9]  Yingying Zhang,et al.  Distinct roles of RIP1–RIP3 hetero- and RIP3–RIP3 homo-interaction in mediating necroptosis , 2014, Cell Death and Differentiation.

[10]  Wei Gan,et al.  Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis , 2016, Science Advances.

[11]  R. Guha,et al.  Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.

[12]  J. Bertin,et al.  Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL* , 2013, The Journal of Biological Chemistry.

[13]  Bo Liu,et al.  Inhibition of Receptor-Interacting Protein Kinase 1 with Necrostatin–1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model , 2017, Scientific Reports.

[14]  Gerard Manning,et al.  Necroptosis and Inflammation. , 2016, Annual review of biochemistry.

[15]  M. Pasparakis,et al.  Cutting Edge: RIPK1 Kinase Inactive Mice Are Viable and Protected from TNF-Induced Necroptosis In Vivo , 2014, The Journal of Immunology.

[16]  Jiahuai Han,et al.  RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway , 2014, Nature Immunology.

[17]  V. Dixit,et al.  Kinase RIP3 Is Dispensable for Normal NF-κBs, Signaling by the B-Cell and T-Cell Receptors, Tumor Necrosis Factor Receptor 1, and Toll-Like Receptors 2 and 4 , 2004, Molecular and Cellular Biology.

[18]  S. Morgan,et al.  Effects of Caspase Inhibitor on Angiotensin II-Induced Abdominal Aortic Aneurysm in Apolipoprotein E–Deficient Mice , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[19]  D. Green,et al.  Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis , 2015, Cell Death and Differentiation.

[20]  D. Vaux,et al.  RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis , 2014, Cell.

[21]  Zhenjie Liu,et al.  Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. , 2015, Circulation research.

[22]  A. Degterev,et al.  Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis. , 2017, Trends in pharmacological sciences.

[23]  Z. Miao,et al.  The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury , 2014, Cell Death and Disease.

[24]  A. Ashkenazi,et al.  NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-α Feedforward Signaling , 2011, Cell.

[25]  K. Newton RIPK1 and RIPK3: critical regulators of inflammation and cell death. , 2015, Trends in cell biology.

[26]  Junying Yuan,et al.  Activation of necroptosis in multiple sclerosis. , 2015, Cell reports.

[27]  G. Superti-Furga,et al.  A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis , 2015, Cell Death and Disease.

[28]  A Daugherty,et al.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. , 2000, The Journal of clinical investigation.

[29]  Michelle C. Schaeffer,et al.  Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase , 2015, Cell Death Discovery.

[30]  Bo Liu,et al.  Receptor-Interacting Protein Kinase 3 Contributes to Abdominal Aortic Aneurysms via Smooth Muscle Cell Necrosis and Inflammation , 2015, Circulation research.

[31]  P. Vandenabeele,et al.  Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.

[32]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[33]  L. Shewchuk,et al.  Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). , 2012, Journal of medicinal chemistry.

[34]  A. Stewart,et al.  Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury , 2018, Neural regeneration research.

[35]  A. Degterev,et al.  Structure-activity relationship study of novel necroptosis inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[36]  Alexei Degterev,et al.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.

[37]  P. Vandenabeele,et al.  Regulated necrosis: disease relevance and therapeutic opportunities , 2016, Nature reviews. Drug discovery.

[38]  Li Jin,et al.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis , 2016, Nature Medicine.

[39]  Stephen J. Capuzzi,et al.  Progress towards a public chemogenomic set for protein kinases and a call for contributions , 2017, bioRxiv.

[40]  N. van Bruggen,et al.  RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury , 2016, Cell Death and Differentiation.

[41]  M. Bertrand,et al.  When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157 , 2017, Cell Death and Differentiation.

[42]  K. Kent,et al.  Accelerated aneurysmal dilation associated with apoptosis and inflammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. , 2012, Journal of vascular surgery.

[43]  Qiao Wu,et al.  A role of RIP3-mediated macrophage necrosis in atherosclerosis development. , 2013, Cell reports.

[44]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[45]  Zhenjie Liu,et al.  Monocyte Chemoattractant Protein-1 (MCP-1) Regulates Macrophage Cytotoxicity in Abdominal Aortic Aneurysm , 2014, PloS one.

[46]  J. Bertin,et al.  Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. , 2015, Cell reports.

[47]  Ethan A Merritt,et al.  Sequence determinants of a specific inactive protein kinase conformation. , 2013, Chemistry & biology.

[48]  P. Leder,et al.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. , 1998, Immunity.

[49]  Stefan Grimm,et al.  The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal , 1998 .

[50]  Junying Yuan,et al.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.

[51]  Sai Zhang,et al.  Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injury , 2017, Scientific Reports.

[52]  J. Diehl,et al.  The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress. , 2016, Current molecular medicine.

[53]  Kenta Moriwaki,et al.  RIP3 induces apoptosis independent of pronecrotic kinase activity. , 2014, Molecular cell.